Emmaus Life Sciences, Inc.
Emmaus Life Sciences, Inc. (EMMA): 3 pipeline candidates · ~22 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
22.2 months
D/E -1.28 · 0% dilution
Lead: Approved
3 candidates
N/A
N/A
A transparent, data-derived signal for Emmaus Life Sciences, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$702K
Cash
$1.1M
Quarterly Burn
$344K
Runway
22.2 mo
Revenue
$2.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Frequently asked questions
How many drug candidates are in Emmaus Life Sciences, Inc.'s pipeline?
Emmaus Life Sciences, Inc. (EMMA) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Emmaus Life Sciences, Inc.'s lead drug candidate?
Emmaus Life Sciences, Inc.'s most advanced tracked candidate is endari (Approved) for Sickle cell disease.
What is Emmaus Life Sciences, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Emmaus Life Sciences, Inc. has approximately 22.2 months of cash runway.
What is Emmaus Life Sciences, Inc.'s market capitalization?
Emmaus Life Sciences, Inc.'s market capitalization is approximately $702K.
Who is the CEO of Emmaus Life Sciences, Inc.?
Mr. Willis C. Lee M.S. is the chief executive officer of Emmaus Life Sciences, Inc. (EMMA).
Get the full picture on Emmaus Life Sciences, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.